Bad Request (Invalid Hostname)

Continued from Page 1

The catheter of choice for long-term epoprostenol therapy is a 6.6 or 9 French single lumen tunneled central venous catheter using an internal jugular vein approach (see Figure 1). The catheter should be tunneled to an exit site low enough so the patient can see the site to care for it independently. Sutures at the site should be removed after two to four weeks.

Each patient is instructed to see his or her local physician within the first month of returning home so the physician can become familiar with the patient’s status, assist with assessment, and monitor treatment, including anticoagulation.

Ongoing treatment

Maintenance for epoprostenol therapy includes regular communication, dose modification, and prevention/management of complications.

Communication. Ask patients to call their health care provider at least every two weeks and obtain the following information:
> Verification of current pump rate
> Number and type of vials being mixed
> Current weight
> Interim change in symptoms (including functional status) or adverse effects, plus relationship to dose changes
> Verification of prothrombin time monitoring, including recent INR
> Status of catheter site
> Any new symptoms or deterioration, which should prompt a clinic visit for evaluation.

Hemodynamic assessment is usually performed after one year of therapy, providing the patient had initial symptomatic improvement and continued with stable symptoms and exercise capacity (as measured by the six-minute walk test). Right heart catheterization is the gold standard for pulmonary hemodynamic assessment. The results of a one-year catheterization should be used to guide future dosing regimens and help make decisions about remaining on the transplant waiting list. The expectation at one year should be improvement in pulmonary hemodynamics, but by no means normalization.

Dosage adjustment. Epoprostenol dosing should be individualized for the patient, with consideration for severity of symptoms, adverse effects, and underlying disease. In general, the dose is gradually increased at regular intervals or depending on symptoms. Many patients who experience improvement in symptoms during initiation of epoprostenol will report increased symptoms after returning home to a more physically challenging environment. Thus, it’s important to have regular contact.

Complications. Prevention of emergencies is always the first line of defense. All potential emergency situations and proper responses should be discussed and “role-played” with patients during initial teaching. The greatest emergency is interruption of the infusion, usually due to pump malfunctions or accidental dislodgement of the catheter. If anything happens to the central venous catheter, the infusion must be continued via a peripheral IV until central access can be reestablished. Encourage patients to wear a medic alert bracelet or carry a laminated card listing their health problems, as well as warnings not to stop the infusion pump.

Infections related to long-term indwelling central lines can be minimized by strict attention to aseptic care. Although some patients have had a central venous catheter for 10 years without infection, others have experienced multiple infections in less than a year. Local site infections should be treated aggressively. The catheter should be removed if site infection recurs despite two courses of antibiotics and immediately if blood cultures are positive.

Epoprostenol therapy can be demanding for both patient and nurse. But through careful planning and follow-up, patients can enjoy significant benefits, and nurses can feel confident that they have done all they can to make sure that patients obtain the best results possible.

Cathy Severson, RN, BSN, is a supervisor at the Pulmonary Hypertension Clinic at Mayo Clinic in Rochester, Minn.

References

1. McLaughlin VV, Shillingon A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circ. 2002;106(12):1477-1482.

2. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Int Med. 1990;112(7):485-491.

3. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296-301.

4. Wax D, Garofano R, Barst RJ. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. Chest. 1999;116(4):914-920.

5. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76-81.

6. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Amer Cardiol. 1999;34(4):1184-1187.